Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 by 31.65 percent. This is a 52.5 percent increase over earnings of $1.20 per share from the same period last year. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million by 3.77 percent. This is a 31.95 percent increase over sales of $88.183 million the same period last year.